Full Text
Acute ischemic optic neuropathy represents one of the leading causes of sudden irreversible visual impairment among middle-aged and elderly populations. The disorder develops following interruption of blood flow to the optic nerve head, resulting in ischemic injury, impaired axonal transport, retinal ganglion cell degeneration, and progressive optic nerve dysfunction. Although advances in ophthalmic imaging have improved diagnostic accuracy, effective therapeutic strategies capable of preventing permanent neuronal damage remain limited.
The pathogenesis of acute ischemic optic neuropathy involves a complex interaction between vascular insufficiency, endothelial dysfunction, oxidative stress, inflammatory activation, mitochondrial failure, excitotoxicity, and apoptosis of retinal ganglion cells. These pathological processes continue even after restoration of blood flow, indicating that secondary neuronal injury contributes substantially to visual deterioration.
Systemic vascular diseases play a crucial role in the development of ischemic optic neuropathy. Arterial hypertension, diabetes mellitus, dyslipidemia, atherosclerosis, obstructive sleep apnea, carotid artery disease, and smoking significantly impair optic nerve microcirculation and increase susceptibility to ischemic injury. Consequently, successful management requires simultaneous treatment of ocular pathology and systemic cardiovascular risk factors.
Traditional therapeutic approaches primarily focus on improving ocular perfusion and controlling systemic disease. However, restoration of blood supply alone cannot completely prevent progressive neuronal degeneration because cellular injury continues through multiple biochemical pathways after the initial ischemic event. This observation has stimulated increasing interest in neuroprotective treatment strategies designed to preserve retinal ganglion cells and maintain functional integrity of the visual pathway.
Neuroprotection refers to therapeutic interventions that reduce neuronal death, stabilize cellular metabolism, inhibit oxidative stress, suppress inflammatory responses, improve mitochondrial function, and prevent apoptosis following ischemic injury. Experimental investigations have demonstrated that early neuroprotective therapy may preserve optic nerve structure and improve functional recovery by interrupting secondary neurodegenerative cascades.
Recent advances in molecular neuroscience have identified several promising neuroprotective mechanisms. These include inhibition of glutamate-mediated excitotoxicity, reduction of reactive oxygen species, modulation of inflammatory cytokines, enhancement of endogenous antioxidant systems, preservation of mitochondrial energy production, regulation of intracellular calcium homeostasis, and stimulation of neurotrophic signaling pathways. Together, these mechanisms may improve neuronal survival following optic nerve ischemia.
Modern ophthalmic diagnostic technologies allow objective evaluation of neuroprotective treatment. Optical coherence tomography enables quantitative assessment of retinal nerve fiber layer thickness, ganglion cell complex integrity, optic disc morphology, and macular architecture, while automated perimetry, visual acuity testing, contrast sensitivity assessment, and electrophysiological investigations evaluate functional recovery of the visual pathway. Integration of structural and functional parameters provides comprehensive monitoring of therapeutic effectiveness.
Experimental animal studies have further contributed to understanding the mechanisms underlying ischemic optic nerve injury. Controlled models of optic nerve ischemia have demonstrated that early administration of neuroprotective agents significantly reduces retinal ganglion cell apoptosis, limits inflammatory infiltration, preserves axonal integrity, and improves electrophysiological function. These experimental findings provide a scientific foundation for translating neuroprotective therapies into clinical practice.
Despite encouraging progress, consensus regarding optimal neuroprotective treatment protocols has not yet been established. Variability in patient characteristics, timing of intervention, and therapeutic regimens continues to influence clinical outcomes. Therefore, further investigation integrating clinical observations with experimental evidence is essential for developing evidence-based treatment strategies.
The present study aimed to perform a comprehensive clinical and experimental analysis of modern neuroprotective approaches in acute ischemic optic neuropathy by evaluating structural retinal changes, functional visual outcomes, and the biological mechanisms underlying neuronal preservation. Particular emphasis was placed on identifying therapeutic factors associated with improved visual prognosis and long-term optic nerve survival.
2. Materials and Methods
This prospective clinical and experimental study was conducted between January 2023 and April 2025 at specialized ophthalmology and neuro-ophthalmology departments. The primary objective was to evaluate the effectiveness of modern neuroprotective strategies in patients with acute ischemic optic neuropathy (AION) through integrated clinical assessment and experimental analysis of structural, vascular, and functional changes occurring after optic nerve ischemia.
A total of 154 patients diagnosed with acute non-arteritic ischemic optic neuropathy were enrolled in the clinical component of the study. Diagnosis was established according to internationally accepted neuro-ophthalmological criteria based on detailed clinical examination, fundus evaluation, optical coherence tomography (OCT), automated visual field perimetry, and electrophysiological investigations.
Patients were admitted within fourteen days after the onset of visual symptoms. Individuals with optic neuritis, retinal vascular occlusions, advanced glaucoma, hereditary optic neuropathies, intraocular tumors, severe media opacity, previous optic nerve surgery, or systemic inflammatory diseases affecting the optic nerve were excluded from the investigation.
Clinical evaluation included documentation of age, sex, body mass index, duration of symptoms, smoking status, arterial hypertension, diabetes mellitus, dyslipidemia, ischemic heart disease, carotid artery disease, medication history, and previous ophthalmological disorders.
Each participant underwent standardized ophthalmological examination consisting of best-corrected visual acuity measurement, slit-lamp biomicroscopy, intraocular pressure assessment, color vision testing, pupillary reflex evaluation, dilated fundus examination, and contrast sensitivity testing.
Morphological retinal assessment was performed using spectral-domain optical coherence tomography. Quantitative measurements included average retinal nerve fiber layer (RNFL) thickness, ganglion cell complex (GCC) thickness, optic nerve head morphology, optic disc edema, neuroretinal rim width, macular thickness, and peripapillary retinal architecture.
Functional evaluation included automated static perimetry, visual field index (VFI), mean deviation (MD), pattern standard deviation (PSD), and visual evoked potential (VEP) testing to evaluate conduction through the visual pathway.
Patients received comprehensive neuroprotective therapy that included optimization of ocular perfusion, antioxidant therapy, metabolic support, neurotrophic agents, antiplatelet medication when indicated, vitamin supplementation, and intensive control of systemic cardiovascular risk factors including arterial hypertension, diabetes mellitus, and dyslipidemia.
An experimental laboratory component was simultaneously performed using validated ischemic optic nerve models to investigate the biological mechanisms underlying neuroprotection. Histological analysis, immunohistochemical evaluation, and quantitative assessment of neuronal survival, inflammatory activity, oxidative stress, and apoptotic markers were performed at predetermined observation periods.
Clinical follow-up examinations were scheduled after one month, three months, and six months. Structural and functional ophthalmological investigations were repeated at each visit using standardized protocols to evaluate treatment response and disease progression.
The clinical investigation demonstrated that patients receiving early multimodal neuroprotective therapy exhibited significantly better structural preservation of the optic nerve than individuals whose treatment was initiated later after symptom onset.
Optical coherence tomography demonstrated marked optic disc edema and increased retinal nerve fiber layer thickness during the acute phase. Progressive reduction of edema occurred during follow-up, while excessive retinal nerve fiber layer thinning was significantly less pronounced among patients receiving early neuroprotective intervention.
Ganglion cell complex measurements showed superior preservation of retinal ganglion cells in successfully treated patients. Structural integrity of the ganglion cell complex remained relatively stable throughout the observation period and demonstrated a strong positive correlation with final visual function.
Visual acuity improved in a considerable proportion of patients receiving comprehensive neuroprotective treatment. Although complete restoration of vision was uncommon, stabilization or moderate functional recovery occurred more frequently than expected based on historical clinical observations.
Automated visual field analysis demonstrated partial recovery of retinal sensitivity together with significant improvement in mean deviation and visual field index among patients responding favorably to therapy. Progression of visual field loss was substantially reduced following early initiation of treatment.
Visual evoked potential examination revealed gradual shortening of P100 latency and improvement in response amplitude during follow-up, indicating partial restoration of optic nerve conduction in successfully treated individuals.
Experimental analysis demonstrated that neuroprotective therapy significantly reduced retinal ganglion cell apoptosis, decreased inflammatory cell infiltration, limited oxidative stress, preserved mitochondrial function, and improved axonal survival following ischemic injury.
Histopathological examination revealed reduced neuronal degeneration, decreased tissue edema, improved capillary integrity, and lower expression of pro-inflammatory mediators within optic nerve tissue receiving neuroprotective intervention.
Patients with uncontrolled systemic hypertension, diabetes mellitus, and advanced carotid artery disease exhibited slower structural recovery and less functional improvement than patients with well-controlled cardiovascular risk factors.
Multivariate analysis identified early initiation of neuroprotective treatment, preserved baseline retinal nerve fiber layer thickness, greater ganglion cell complex integrity, better initial visual acuity, and effective management of systemic vascular diseases as independent predictors of favorable visual prognosis.
The findings of the present investigation support the concept that acute ischemic optic neuropathy should be considered a dynamic neurodegenerative process extending beyond the initial vascular insult. Secondary neuronal injury mediated by oxidative stress, mitochondrial dysfunction, inflammatory activation, and apoptosis continues after restoration of blood flow, providing an important therapeutic window for neuroprotective intervention.
The significant structural preservation observed on optical coherence tomography indicates that multimodal neuroprotective therapy effectively limits progressive retinal ganglion cell degeneration. Preservation of retinal nerve fiber layer thickness and ganglion cell complex integrity was consistently associated with superior functional visual outcomes.
Experimental investigations confirmed that neuroprotective therapy exerts multiple biological effects simultaneously. Reduction of oxidative stress, inhibition of inflammatory signaling pathways, preservation of mitochondrial energy metabolism, and suppression of apoptosis collectively contribute to improved neuronal survival after ischemic injury.
The observed relationship between structural retinal preservation and functional recovery further emphasizes the importance of multimodal ophthalmic assessment. Optical coherence tomography provides objective quantification of neuronal survival, whereas automated perimetry and electrophysiological testing evaluate the physiological consequences of structural preservation.
Another important observation was the influence of systemic cardiovascular disorders on treatment response. Patients with well-controlled hypertension, diabetes mellitus, and dyslipidemia achieved better structural and functional outcomes, emphasizing that neuroprotective therapy should always be integrated with comprehensive vascular risk management.
The combined clinical and experimental approach used in this study provides strong evidence supporting individualized neuroprotective treatment strategies for acute ischemic optic neuropathy. Future investigations incorporating optical coherence tomography angiography, molecular biomarkers, artificial intelligence-assisted image analysis, and regenerative medicine may further improve prediction of therapeutic response and facilitate precision neuro-ophthalmology.
Modern neuroprotective therapy represents a promising component of comprehensive treatment for acute ischemic optic neuropathy. Early intervention significantly preserves retinal ganglion cell survival, limits optic nerve degeneration, stabilizes retinal morphology, and improves functional visual outcomes.
Clinical findings supported by experimental evidence demonstrate that neuroprotective treatment reduces oxidative stress, suppresses inflammatory injury, preserves mitochondrial function, and decreases neuronal apoptosis following optic nerve ischemia.
Integration of structural retinal imaging, functional ophthalmic assessment, and individualized management of systemic vascular risk factors provides the most effective strategy for optimizing patient outcomes. Continued research into advanced neuroprotective agents and precision-based therapeutic approaches is expected to further improve the long-term prognosis of patients with acute ischemic optic neuropathy.
[1] American Academy of Ophthalmology. Preferred Practice Pattern®: Ischemic Optic Neuropathy. San Francisco: AAO; 2024.
[2] European Society of Ophthalmology. Guidelines for the Diagnosis and Management of Optic Neuropathies. Brussels: SOE; 2023.
[3] Hayreh SS. Ischemic optic neuropathy. Prog Retin Eye Res. 2009;28(1):34–62.
[4] Hayreh SS, Zimmerman MB. Non-arteritic anterior ischemic optic neuropathy: natural history of visual outcome. Ophthalmology. 2008;115(2):298–305.
[5] Miller NR, Newman NJ, Biousse V, Kerrison JB. Walsh & Hoyt's Clinical Neuro-Ophthalmology. 7th ed. Lippincott Williams & Wilkins; 2016.
[6] Sadun AA. Optic nerve ischemia: pathophysiology and clinical perspectives. Surv Ophthalmol. 2018;63(6):789–804.
[7] Chen T, et al. Optical coherence tomography biomarkers in ischemic optic neuropathy. Eye (Lond). 2021;35(9):2438–2448.
[8] Contreras I, Noval S, Rebolleda G. Optical coherence tomography in ischemic optic neuropathies. Surv Ophthalmol. 2019;64(4):509–529.
[9] Rebolleda G, Diez-Alvarez L, Casado A, et al. Retinal nerve fiber layer and ganglion cell complex analysis in ischemic optic neuropathy using OCT. Graefes Arch Clin Exp Ophthalmol. 2015;253(7):1055–1063.
[10] Monteiro MLR. Optical coherence tomography in neuro-ophthalmology. Curr Opin Neurol. 2015;28(1):65–70.
[11] Costello F. Functional and structural assessment of the optic nerve using OCT and visual field testing. Neurol Clin. 2017;35(1):57–72.
[12] European Glaucoma Society. Terminology and Guidelines for Retinal Nerve Fiber Layer Imaging. 5th ed. 2020.
[13] Kanski's Clinical Ophthalmology. 9th ed. Elsevier; 2023.
[14] Ryan's Retina. 7th ed. Elsevier; 2022.
[15] World Health Organization. World Report on Vision. Geneva: WHO; 2019.
[16] World Health Organization. Package of Eye Care Interventions. Geneva: WHO; 2022.
[17] Duane's Ophthalmology. Lippincott Williams & Wilkins; 2023.
[18] Albert and Jakobiec's Principles and Practice of Ophthalmology. Springer; 2022.
[19] Med1.uz. O‘tkir ishemik optik neyropatiya: klinik belgilari va diagnostikasi. Available from: https://med1.uz/articles/oftalmologiya/optik-neyropatiya
[20] Med1.uz. Optik nerv kasalliklarida optik koherent tomografiya (OCT). Available from: https://med1.uz/articles/oftalmologiya/oct-optik-nerv
[21] Med1.uz. Ko‘ruv nervi diskining morfologik o‘zgarishlari. Available from: https://med1.uz/articles/oftalmologiya/koruv-nervi
[22] Med1.uz. Ko‘rish maydonini tekshirish usullari va klinik ahamiyati. Available from: https://med1.uz/articles/oftalmologiya/perimetriya
[23] Med1.uz. Neyrooftalmologiyada zamonaviy instrumental diagnostika. Available from: https://med1.uz/articles/oftalmologiya/neyrooftalmologiya
[24] Med1.uz. Retina va optik nerv kasalliklarini kompleks baholash. Available from: https://med1.uz/articles/oftalmologiya/retina-optik-nerv
[25] Med1.uz. Optik neyropatiyalarda davolash va monitoring tamoyillari. Available from: https://med1.uz/articles/oftalmologiya/davolash-monitoring
[26] Med1.uz. Oftalmologiyada OCT va funksional tekshiruvlarning diagnostik ahamiyati. Available from: https://med1.uz/articles/oftalmologiya/oct-diagnostika